Skip to content
lifestyle.ribbon.co
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Faron Pharmaceuticals
New Review Published in Immunotherapy Highlights the Potential for Clever-1 Inhibition with bexmarilimab to Become the Cornerstone of Next-Generation, Multi-Indication Cancer Immunotherapy
January 29, 2026
Faron Expands Bexmarilimab Program in Solid Tumors with a Randomized Phase I/II BEXAR IIT in Metastatic Soft-Tissue Sarcoma
January 27, 2026
Faron Pharmaceuticals Ltd: PDMR Dealing
January 13, 2026
Faron Announces Strategic Collaboration with The Institute for Cancer Research to Launch BLAZE Trial, Targeting Immunotherapy Resistance in Cancer
December 22, 2025
Composition of Faron Pharmaceutical’s Shareholders’ Nomination Board
December 19, 2025
←
Previous Page
1
2
3
4